Meglitinides Drug-Drug Interaction Table

Why Meglitinide Interactions Deserve a Dedicated Table

Meglitinides occupy a narrow therapeutic space as prandial insulin secretagogues with rapid onset and short duration. Their interaction profile is deceptively complex because repaglinide sits at the intersection of CYP2C8 metabolism, CYP3A4 metabolism, and OATP1B1-mediated hepatic uptake [1]. A single co-prescribed drug can affect more than one of these pathways simultaneously, producing AUC changes that far exceed what either mechanism alone would predict.

Dual-Mechanism Vulnerability of Repaglinide

Gemfibrozil illustrates this principle. It inhibits both CYP2C8 and OATP1B1. In a landmark pharmacokinetic study by Niemi et al. (2003), gemfibrozil increased repaglinide AUC 8.1-fold and prolonged blood glucose reduction for more than 7 hours beyond the expected window [2]. The FDA subsequently added a contraindication to the repaglinide label. No other oral antidiabetic carries this specific restriction.

Nateglinide: A Simpler but Not Interaction-Free Profile

Nateglinide routes primarily through CYP2C9 with a minor CYP3A4 contribution [3]. It is not an OATP1B1 substrate, which removes one vulnerability layer. Strong CYP2C9 inhibitors (fluconazole, amiodarone) still raise nateglinide exposure enough to warrant glucose monitoring or dose adjustment.

Repaglinide Interaction Table: CYP2C8 Inhibitors and Inducers

The CYP2C8 pathway accounts for roughly 60-70% of repaglinide oxidative metabolism [1]. Any drug that materially alters CYP2C8 activity will shift repaglinide concentrations.

Strong CYP2C8 Inhibitors

| Interacting Drug | Mechanism | Effect on Repaglinide | Clinical Action | |---|---|---|---| | Gemfibrozil | CYP2C8 inhibition + OATP1B1 inhibition | AUC increased ~8.1-fold [2] | Contraindicated. Use fenofibrate if a fibrate is needed. | | Clopidogrel (glucuronide metabolite) | CYP2C8 inhibition | AUC increased ~3.9- to 5.1-fold [4] | Avoid combination. Consider prasugrel or ticagrelor with glucose monitoring. | | Trimethoprim | CYP2C8 inhibition | AUC increased ~1.6-fold [5] | Monitor blood glucose. Short courses (<5 days) may be manageable with dose vigilance. |

The American Diabetes Association's 2024 Standards of Care states: "Clinicians should review all concomitant medications for CYP2C8 interaction potential before initiating repaglinide" [6].

Moderate CYP2C8 Inhibitors and Inducers

| Interacting Drug | Mechanism | Effect on Repaglinide | Clinical Action | |---|---|---|---| | Deferasirox | CYP2C8 inhibition (moderate) | AUC increase expected 1.5- to 2-fold | Monitor glucose closely; consider dose reduction. | | Teriflunomide | CYP2C8 inhibition (moderate) | Predicted AUC increase ~1.5-fold | Monitor fasting and postprandial glucose for 2 weeks after initiation. | | Rifampin | CYP2C8 induction + CYP3A4 induction + OATP1B1 induction (complex) | AUC decreased ~50-80% with chronic use; transient AUC increase on day 1 via OATP1B1 inhibition [7] | Avoid if possible. If co-administered, expect loss of glycemic control after 3-5 days. |

The rifampin interaction deserves special attention. On day one of co-administration, rifampin acutely inhibits OATP1B1, raising repaglinide exposure. By day 5-7, enzyme induction dominates and repaglinide AUC falls well below therapeutic range [7]. Prescribers who see an initial glucose drop should not assume the combination is safe long-term.

Repaglinide Interaction Table: CYP3A4 Pathway

CYP3A4 handles a smaller fraction of repaglinide clearance (roughly 30%), but strong inhibitors can still produce clinically meaningful AUC increases, particularly when CYP2C8 is simultaneously compromised [1].

Strong CYP3A4 Inhibitors

| Interacting Drug | Mechanism | Effect on Repaglinide | Clinical Action | |---|---|---|---| | Itraconazole | CYP3A4 inhibition | AUC increased ~1.4-fold [8] | Monitor glucose. Modest effect alone, but additive if CYP2C8 is also inhibited. | | Clarithromycin | CYP3A4 inhibition | AUC increase expected ~1.4- to 1.7-fold | Use azithromycin as alternative (no CYP3A4 effect). Monitor glucose if clarithromycin is unavoidable. | | Ketoconazole | CYP3A4 inhibition | AUC increased ~1.2-fold [8] | Minimal standalone effect. Watch for stacking with CYP2C8 inhibitors. |

The Stacking Problem

When a patient takes a CYP2C8 inhibitor and a CYP3A4 inhibitor simultaneously, repaglinide clearance through both routes drops. Niemi et al. Demonstrated that itraconazole alone increased repaglinide AUC 1.4-fold, but itraconazole plus gemfibrozil produced a 19.4-fold AUC increase, far exceeding the sum of individual effects [8]. This combination is pharmacologically predictable but routinely underestimated in clinical practice.

Dr. Mikko Niemi of the University of Helsinki noted: "The magnitude of the gemfibrozil-itraconazole combination effect on repaglinide pharmacokinetics was unexpectedly large and demonstrates why interaction studies with single perpetrator drugs may underpredict real-world exposure changes" [8].

Repaglinide Interaction Table: OATP1B1 Transporter

Repaglinide enters hepatocytes via OATP1B1, encoded by the SLCO1B1 gene. Drugs or genetic variants that reduce OATP1B1 function increase systemic repaglinide concentrations by slowing hepatic uptake [9].

OATP1B1 Inhibitors

| Interacting Drug | Mechanism | Effect on Repaglinide | Clinical Action | |---|---|---|---| | Cyclosporine | OATP1B1 inhibition + CYP3A4 inhibition | AUC increased ~2.5-fold [10] | Reduce repaglinide dose. Monitor glucose at least weekly during co-administration. | | Eltrombopag | OATP1B1 inhibition | AUC increase expected ~1.5- to 2-fold | Monitor glucose. Limited direct PK data; extrapolated from probe substrate studies. | | Gemfibrozil | OATP1B1 inhibition + CYP2C8 inhibition | See CYP2C8 section; 8.1-fold AUC increase [2] | Contraindicated. |

Pharmacogenomic Considerations

Patients carrying the SLCO1B1 521T>C variant (rs4149056) exhibit reduced OATP1B1 function at baseline. In homozygous carriers (CC genotype), repaglinide AUC is approximately 107% higher compared to wild-type (TT) [9]. Adding an OATP1B1 inhibitor on top of this genetic deficit compounds the exposure increase. The Clinical Pharmacogenetics Implementation Consortium (CPIC) does not yet have a formal guideline for repaglinide, but the Dutch Pharmacogenetics Working Group recommends considering dose reduction in SLCO1B1 poor-function carriers [11].

Nateglinide Interaction Table: CYP2C9 Pathway

Nateglinide metabolism runs primarily through CYP2C9, with a minor CYP3A4 contribution [3]. The interaction profile is narrower than repaglinide's because nateglinide lacks OATP1B1 dependence.

CYP2C9 Inhibitors

| Interacting Drug | Mechanism | Effect on Nateglinide | Clinical Action | |---|---|---|---| | Fluconazole | Strong CYP2C9 inhibition | AUC increased ~1.5-fold [12] | Monitor glucose. Consider dose reduction for courses >3 days. | | Amiodarone | Moderate CYP2C9 inhibition | AUC increase expected ~1.3-fold | Monitor glucose during loading and maintenance phases. | | Sulfaphenazole | Strong CYP2C9 inhibition (research probe) | In vitro Ki demonstrates potent inhibition [3] | Not commonly co-prescribed; listed for mechanistic completeness. | | Voriconazole | Strong CYP2C9 inhibition | AUC increase expected ~1.4- to 1.6-fold | Monitor glucose. Use alternative antifungal if feasible. |

CYP2C9 Pharmacogenomics

CYP2C9 poor metabolizers (*2/*3 or *3/3 genotypes) clear nateglinide more slowly. The CYP2C93 allele reduces nateglinide clearance by approximately 25-30% in heterozygous carriers [13]. This mirrors the well-documented CYP2C9 effect on sulfonylureas, though nateglinide's short half-life (~1.5 hours) provides a partial safety buffer compared to longer-acting agents like glimepiride.

Shared Pharmacodynamic Interactions

Both meglitinides share pharmacodynamic interactions that amplify or blunt their glucose-lowering effect. These are mechanism-independent and apply regardless of which metabolic pathway is relevant.

Hypoglycemia Potentiators

| Interacting Drug/Class | Mechanism | Clinical Action | |---|---|---| | Sulfonylureas | Additive insulin secretion | Avoid co-prescribing. Redundant mechanism with higher hypoglycemia risk. | | Insulin | Additive hypoglycemia | If combined, reduce meglitinide dose and increase SMBG frequency. | | ACE inhibitors | Possible enhanced insulin sensitivity [14] | Monitor glucose when initiating. Dose adjustment rarely needed. | | Salicylates (high-dose) | Increased insulin secretion, reduced hepatic glucose output | Relevant mainly at anti-inflammatory doses (>3 g/day). | | Alcohol (acute ingestion) | Inhibits hepatic gluconeogenesis | Counsel patients on hypoglycemia risk with fasting plus alcohol. |

Hyperglycemia Promoters

| Interacting Drug/Class | Mechanism | Clinical Action | |---|---|---| | Corticosteroids (systemic) | Insulin resistance, hepatic glucose output | May need to increase meglitinide dose or add basal insulin for courses >5 days. | | Thiazide diuretics | Impaired insulin secretion, potassium depletion | Monitor glucose and potassium. Effect is dose-dependent. | | Sympathomimetics | Counter-regulatory hormone release | Monitor glucose during acute use. | | Atypical antipsychotics (olanzapine, clozapine) | Weight gain, insulin resistance | Monitor A1c quarterly if co-prescribed long-term [6]. | | Rifampin (chronic) | CYP2C8/3A4 induction (repaglinide); general enzyme induction | Loss of glycemic control expected by day 5-7. See CYP2C8 section. |

Beta-Blockers and Masked Hypoglycemia

Non-selective beta-blockers (propranolol, nadolol) blunt tachycardia and tremor, the two adrenergic warning signs of hypoglycemia. Selective beta-1 blockers (metoprolol, bisoprolol) preserve these warnings at standard doses but may mask them at higher doses. The 2024 ADA Standards of Care recommends educating patients on non-adrenergic hypoglycemia symptoms (confusion, diaphoresis, hunger) when beta-blockers are co-prescribed with any insulin secretagogue [6].

Practical Workflow for Interaction Screening

A systematic screening approach reduces the chance of missing stacked interactions, especially for repaglinide.

Step 1: Identify the Meglitinide

Repaglinide carries the broader interaction liability. If the patient is on nateglinide, the CYP2C8/OATP1B1 interactions do not apply.

Step 2: Check CYP2C8 Status (Repaglinide Only)

Screen for gemfibrozil (contraindicated), clopidogrel (avoid), and trimethoprim (monitor). If any strong CYP2C8 inhibitor is present, do not add a CYP3A4 inhibitor without quantifying the stacking risk.

Step 3: Check OATP1B1 Status (Repaglinide Only)

Cyclosporine is the most commonly encountered OATP1B1 inhibitor in this context. Post-transplant patients on cyclosporine who need prandial glucose control should use nateglinide or a non-secretagogue alternative.

Step 4: Check CYP2C9 Status (Nateglinide Only)

Fluconazole and amiodarone are the most frequent culprits. Short antifungal courses (<3 days) are lower risk. Amiodarone's extremely long half-life (~40-55 days) means the interaction persists for weeks after discontinuation.

Step 5: Review Pharmacodynamic Layer

Regardless of pharmacokinetic findings, confirm whether the patient takes any drug that independently raises hypoglycemia risk (insulin, sulfonylureas, high-dose salicylates) or antagonizes glucose lowering (systemic corticosteroids, thiazides).

When to Choose Nateglinide Over Repaglinide (and Vice Versa)

The interaction profile itself can drive agent selection within the class.

Choose nateglinide when the patient takes a CYP2C8 inhibitor that cannot be discontinued, requires cyclosporine, or carries a known SLCO1B1 poor-function genotype. Nateglinide sidesteps all three vulnerabilities.

Choose repaglinide when the patient takes fluconazole or amiodarone long-term, carries a CYP2C93/3 genotype, or needs stronger postprandial glucose reduction. Repaglinide's greater potency (roughly 3- to 5-fold on a milligram basis) and longer track record in outcome-adjacent studies give it a clinical edge when its interaction risks are manageable [15].

Neither agent is preferred when a fibrate is indicated for severe hypertriglyceridemia. Fenofibrate does not inhibit CYP2C8 and is safe with repaglinide [2], but if gemfibrozil is specifically required (rare), both meglitinides should be replaced with a non-secretagogue.